The FDA recently approved Granix for self-administration, and Harvard Pilgrim will now cover it under the pharmacy benefit on the following tiers:
- Tier 3 on the 3-Tier Premium Formulary
- Tier 4 on the 4-Tier Premium Formulary
- Tier 3 on the 4-Tier Value Formulary
- Tier 4 on the 5-Tier Value Formulary
Granix (tbo-filgrastim) is a leukocyte growth factor prescribed to people with nonmyeloid malignancies who are receiving chemotherapy that affects the bone marrow to decrease the length of time that certain white blood cells (neutrophils) are very low (severe neutropenia).